Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-CD45 antibody - Hematopoietic Stem Cell Marker (ab10559)

Key features and details

  • Rabbit polyclonal to CD45 - Hematopoietic Stem Cell Marker
  • Suitable for: WB, IHC-P
  • Reacts with: Human
  • Isotype: IgG

Overview

  • Product name

    Anti-CD45 antibody - Hematopoietic Stem Cell Marker
    See all CD45 primary antibodies

  • Description

    Rabbit polyclonal to CD45 - Hematopoietic Stem Cell Marker

  • Host species

    Rabbit

  • Tested applications

    Suitable for: WB, IHC-Pmore details

  • Species reactivity

    Reacts with: Human
    Predicted to work with: Pig, Monkey

  • Immunogen

    Synthetic peptide corresponding to Human CD45 aa 1250 to the C-terminus conjugated to keyhole limpet haemocyanin.
    (Peptide available as ab17550)

Applications

Our Abpromise guarantee covers the use of ab10559 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500. Detects a band of approximately 155 kDa (predicted molecular weight: 147 kDa).
IHC-P Use a concentration of 1 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

Target

  • Function

    Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.

  • Involvement in disease

    Defects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
    Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.

  • Sequence similarities

    Belongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
    Contains 2 fibronectin type-III domains.
    Contains 2 tyrosine-protein phosphatase domains.

  • Domain

    The first PTPase domain interacts with SKAP1.

  • Post-translational
    modifications

    Heavily N- and O-glycosylated.

  • Cellular localization

    Membrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
  • Information by UniProt

  • Database links

    • Alternative names

      • B220 antibody
      • CD 45 antibody
      • CD45 antibody
      • CD45 antigen antibody
      • CD45R antibody
      • GP180 antibody
      • L-CA antibody
      • LCA antibody
      • Leukocyte common antigen antibody
      • loc antibody
      • Ly-5 antibody
      • LY5 antibody
      • Ly5, homolog of antibody
      • Lyt-4 antibody
      • OTTHUMP00000033813 antibody
      • OTTHUMP00000033816 antibody
      • OTTHUMP00000033817 antibody
      • OTTHUMP00000038574 antibody
      • Protein tyrosine phosphatase receptor type c polypeptide antibody
      • Protein tyrosine phosphatase, receptor type C antibody
      • protein tyrosine phosphatase, receptor type, C antibody
      • Protein tyrosine phosphatase, receptor type, c polypeptide antibody
      • Ptprc antibody
      • PTPRC_HUMAN antibody
      • Receptor-type tyrosine-protein phosphatase C antibody
      • T200 antibody
      • T200 glycoprotein antibody
      • T200 leukocyte common antigen antibody
      see all

    Images

    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD45 antibody - Hematopoietic Stem Cell Marker (ab10559)
      Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD45 antibody - Hematopoietic Stem Cell Marker (ab10559)

      IHC image of ab10559 staining in human Hodgkins lymphoma formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab10559, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
      For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

    • Western blot - Anti-CD45 antibody - Hematopoietic Stem Cell Marker (ab10559)
      Western blot - Anti-CD45 antibody - Hematopoietic Stem Cell Marker (ab10559)

      ab10559  rabbit polyclonal to CD45  (1/500) with secondary goat anti-rabbit IgG ab6721 (1/5000).

      Expected molecular weight: 147 kDa. WB exposure time: 1min 30sec    

      Lanes 1 to 10: 20µg of cell lysate per lane
      Lanes 6 to 10: ab17550 CD45 blocking peptide used at 1µg/ml

      Lane 1: HeLa Nuclear Extract (ab10559)
      Lane 2: HeLa Whole Cell Lysate (ab10559)
      Lane 3: A431 Whole Cell Lysate (ab10559)
      Lane 4: Jurkat Whole Cell Lysate (ab10559)
      Lane 5: HEK293 Whole Cell Lysate (ab10559)
      Lane 6: HeLa Nuclear Extract (ab10559+ ab17550)
      Lane 7: HeLa Whole Cell Lysate (ab10559+ ab17550)
      Lane 8: A431 Whole Cell Lysate (ab10559+ ab17550)
      Lane 9: Jurkat Whole Cell Lysate (ab10559+ ab17550)
      Lane 10: HEK293 Whole Cell Lysate (ab10559+ ab17550)

      A strong band, slightly higher was seen in Jurkat cell lysate. The band was blocked using the immunising peptide (ab17550). It is likely that the band is CD45.

    References (22)

    Publishing research using ab10559? Please let us know so that we can cite the reference in this datasheet.

    ab10559 has been referenced in 22 publications.

    • Coelho S  et al. Ultraprecise single-molecule localization microscopy enables in situ distance measurements in intact cells. Sci Adv 6:eaay8271 (2020). PubMed: 32494604
    • Kellaway SG  et al. Increased proliferation and altered cell cycle regulation in pancreatic stem cells derived from patients with congenital hyperinsulinism. PLoS One 14:e0222350 (2019). PubMed: 31525223
    • Li J  et al. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T Cells. Immunity 48:773-786.e5 (2018). PubMed: 29625896
    • Wang H  et al. The human umbilical cord stem cells improve the viability of OA degenerated chondrocytes. Mol Med Rep 17:4474-4482 (2018). PubMed: 29328479
    • Sikorski K  et al. A high-throughput pipeline for validation of antibodies. Nat Methods 15:909-912 (2018). PubMed: 30377371
    View all Publications for this product

    Images

    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD45 antibody - Hematopoietic Stem Cell Marker (ab10559)
      Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD45 antibody - Hematopoietic Stem Cell Marker (ab10559)

      IHC image of ab10559 staining in human Hodgkins lymphoma formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab10559, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
      For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

    • Western blot - Anti-CD45 antibody - Hematopoietic Stem Cell Marker (ab10559)
      Western blot - Anti-CD45 antibody - Hematopoietic Stem Cell Marker (ab10559)

      ab10559  rabbit polyclonal to CD45  (1/500) with secondary goat anti-rabbit IgG ab6721 (1/5000).

      Expected molecular weight: 147 kDa. WB exposure time: 1min 30sec    

      Lanes 1 to 10: 20µg of cell lysate per lane
      Lanes 6 to 10: ab17550 CD45 blocking peptide used at 1µg/ml

      Lane 1: HeLa Nuclear Extract (ab10559)
      Lane 2: HeLa Whole Cell Lysate (ab10559)
      Lane 3: A431 Whole Cell Lysate (ab10559)
      Lane 4: Jurkat Whole Cell Lysate (ab10559)
      Lane 5: HEK293 Whole Cell Lysate (ab10559)
      Lane 6: HeLa Nuclear Extract (ab10559+ ab17550)
      Lane 7: HeLa Whole Cell Lysate (ab10559+ ab17550)
      Lane 8: A431 Whole Cell Lysate (ab10559+ ab17550)
      Lane 9: Jurkat Whole Cell Lysate (ab10559+ ab17550)
      Lane 10: HEK293 Whole Cell Lysate (ab10559+ ab17550)

      A strong band, slightly higher was seen in Jurkat cell lysate. The band was blocked using the immunising peptide (ab17550). It is likely that the band is CD45.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Alternative products to Anti-CD45 antibody - Hematopoietic Stem Cell Marker (ab10559)

    Sign up